Have you ever had breast cancer, lobular carcinoma in situ or atypical ductal hyperplasia?
If no: Go to the next question. If yes: If you had breast cancer, including ductal carcinoma in situ (DCIS), did you take tamoxifen as part of your treatment? If yes: Tamoxifen should only be taken for 5 years, so tamoxifen would not be expected to reduce your risk any further. One of the newer aromatase inhibitors may be an option for you. (We will talk about these later on.) You may want to ask your doctor about this. If no: The BCPT study did not include women who had breast cancer (or DCIS) in the past. Talk to your doctor about whether taking tamoxifen to reduce your risk is an option for you now. If you had lobular carcinoma in situ (LCIS) and are 35 or older: Doctors consider the breast cancer risk of women who have had LCIS to be high enough to consider taking tamoxifen, so this may be an option for you. When the BCPT study was set up, it was decided that any woman with LCIS automatically qualified to take part because LCIS is a risk factor for breast cancer. If you had atypica
